Brief: Scope Fluidics Unit Signs Deal To Conduct Clinical Trials For FDA Certification
25/06/2025 12:28
June 25 (Reuters) - Scope Fluidics SA SCPP.WA: UNIT BACTEROMIC SINGS AGREEMENT TO CONDUCT CLINICAL TRIALS FOR FDA CERTIFICATION ESTIMATED COST OF STUDIES ABOUT $2 MILLION AIMS FOR FDA CERTIFICATION OF BACTEROMIC SYSTEM IN 2027 Source text: nEM92C7wVa Further company coverage: SCPP.WA (Reporting by Gdańsk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Scope Fluidics SA
See all newsBrief: Scope Fluidics Extends Deadline For First Milestone Of Hybolic Project To End Of Q3 2026
Brief: Scope Fluidics Says Bacteromic Granted U.S. Patent 'Microfluidic Chip'
Brief: Scope Fluidics Q1 Net Loss At 13.5 Million Zlotys
Brief: Scope Fluidics Unit Bacteromic Starts Collaboration With US Research Center For FDA Registration Trials
Brief: Scope Fluidics FY Net Loss At 46.4 Million Zlotys